Edoc

PowerSchool Partners with Scribbles to add More than 2,000 Colleges to the Naviance eDocs Network

Retrieved on: 
Wednesday, April 12, 2023
University, Data Management, Primary, Secondary, Education, Technology, Preschool, Software, Networks, Internet, Other Education, Hardware, Partnership, Edoc, School, Student, Documentation, NYSE, Counselor, Nursing, Naviance, Pearson Education

PowerSchool (NYSE: PWSC), the leading provider of cloud-based software for K-12 education in North America, today announced a partnership with Scribbles Software and PowerSchool Naviance .

Key Points: 
  • PowerSchool (NYSE: PWSC), the leading provider of cloud-based software for K-12 education in North America, today announced a partnership with Scribbles Software and PowerSchool Naviance .
  • This partnership will nearly double the number of institutions in the Naviance eDocs network, greatly expanding college access for high school students.
  • “Scribbles is thrilled to partner with Naviance to expand access to a broader higher education network.
  • Through this partnership, districts, and schools will be able to empower more students with greater access to life-changing opportunities,” said Marshall Simmonds, Vice President of Sales for Scribbles Software.

Edoc Service, Inc., a 100% Remote Company, Announces Vice President Promotion

Retrieved on: 
Monday, February 6, 2023
Growth, Organization, Culture, Mullaney, Edoc, Aluterus scriptus, Freedom, Management

WEST CHESTER, Ohio, Feb. 6, 2023 /PRNewswire-PRWeb/ -- Edoc Service, Inc., a totally remote company that offers services for greater productivity and collaboration, has announced a promotion as the company enters its next phase of growth.

Key Points: 
  • WEST CHESTER, Ohio, Feb. 6, 2023 /PRNewswire-PRWeb/ -- Edoc Service, Inc., a totally remote company that offers services for greater productivity and collaboration, has announced a promotion as the company enters its next phase of growth.
  • Kim Geiger, who has a tenure of more than 9 years with the company, has been named Vice President.
  • Edoc Service, Inc. is a 24/7, always-on business, offering tools and services to help other companies be more productive and work more virtually.
  • Nearly 26 years ago, Edoc Service was founded by CEO/President Jim Mullaney as a work-from-home administrative support services firm.

RealTime Software Solutions Acquires Complion

Retrieved on: 
Wednesday, December 7, 2022
Factor X, Clinical data management, NIH, Acquisition, Clinical trial management system, Edoc, Partnership, Research, Hospital, CTMS, Cros, Academic health science centre, ESourcing Capability Model, Epiregulin, MD–PhD, AMCS, SAN, TEXT, Pharmaceutical industry, Online shopping, Text

SAN ANTONIO, Dec. 7, 2022 /PRNewswire/ -- RealTime Software Solutions, LLC, a leader in cloud-based software solutions for the clinical research industry, is pleased to announce the acquisition of Complion, Inc., a leading electronic regulatory (eReg)/electronic Investigator Site Files (eISF) solution provider for clinical research sites, academic medical centers (AMCs), hospitals, health systems, sponsors and contract research organizations (CROs).

Key Points: 
  • SAN ANTONIO, Dec. 7, 2022 /PRNewswire/ -- RealTime Software Solutions, LLC, a leader in cloud-based software solutions for the clinical research industry, is pleased to announce the acquisition of Complion, Inc., a leading electronic regulatory (eReg)/electronic Investigator Site Files (eISF) solution provider for clinical research sites, academic medical centers (AMCs), hospitals, health systems, sponsors and contract research organizations (CROs).
  • The partnership of RealTime and Complion bolsters the combined organization's position as a leading provider of eClinical solutions to make clinical research processes more efficient and compliant.
  • "This combination accelerates our mission to deliver leading eRegulatory and additional innovative solutions from RealTime to our customers."
  • About RealTime: RealTime Software Solutions, LLC provides innovative software solutions for clinical research sites, site networks, sponsors and CROs to manage complex clinical research processes with powerful, user-friendly interfaces that are revolutionizing how research gets done.

Edoc Acquisition Corp. Announces Termination of Merger Agreement with Calidi Biotherapeutics, Inc.

Retrieved on: 
Friday, August 12, 2022
ADOC, U.S. Securities and Exchange Commission, Tripura Merger Agreement, Forward-looking statement, Name, GLOBE, Business architecture, SEC, Sale, Prospectus, Security (finance), Annual report, Proxy, Acquisition, Extension, Securities Act of 1933, Nasdaq, Person, Edoc

New York, NY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Edoc Acquisition Corp. (Nasdaq: ADOC, ADOCR, ADOCW, EDOC or the Company), a special purpose acquisition company, announced today the termination of its previously announced agreement and plan of merger (the Merger Agreement) with Calidi Biotherapeutics, Inc. (Calidi).

Key Points: 
  • New York, NY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Edoc Acquisition Corp. (Nasdaq: ADOC, ADOCR, ADOCW, EDOC or the Company), a special purpose acquisition company, announced today the termination of its previously announced agreement and plan of merger (the Merger Agreement) with Calidi Biotherapeutics, Inc. (Calidi).
  • As a result of the termination of the Merger Agreement, Edoc intends to promptly begin simultaneously evaluating other possible business combination targets.
  • Edoc Acquisition Corp. is a blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities.
  • Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements.

Edoc Acquisition Corp. Announce Postponement of Special Meeting of Shareholders to Extend the Deadline to Consummate an Initial Business Combination

Retrieved on: 
Friday, August 12, 2022
ADOC, U.S. Securities and Exchange Commission, Securities Act of 1933, Forward-looking statement, Name, GLOBE, NEW, Kitchen Party (girl group), 1345 Avenue of the Americas, SEC, Prospectus, Mass meeting, Sale, Security (finance), Proxy, Director, Acquisition, Extension, Special, Person, Association, Edoc, Eastern Time Zone

The Special Meeting has been postponed until August 12, 2022 at 8:00 p.m. Eastern Time.

Key Points: 
  • The Special Meeting has been postponed until August 12, 2022 at 8:00 p.m. Eastern Time.
  • The record date for the determination of shareholders entitled to vote at the Special Meeting, including all adjournments thereof, remains July 18, 2022.
  • As of the date of this press release, a sufficient number of Edocs shareholders have voted to approve the proposed extension to consummate an initial business combination.
  • The postponement of the Special Meeting is intended to permit more time to satisfy all conditions necessary to effect the Extension.

Edoc Acquisition Corp. Reminds Shareholders to Vote and Announces Additional Contribution for Extension Amendment

Retrieved on: 
Thursday, August 4, 2022
ADOC, Telephone, U.S. Securities and Exchange Commission, Securities Act of 1933, Forward-looking statement, Name, GLOBE, Business architecture, SEC, Prospectus, Sale, Contribution, Eastern Time Zone, Security (finance), Calendar, Company, Proxy, Acquisition, Extension, Special, Potyvirus, Sponsor, Person, Edoc

An extraordinary general meeting of the Companys shareholders (Special Meeting) to approve the Extension Amendment will be held on August 12, 2022 at 10:00 AM, Eastern Time and can be accessed virtually by visiting https://www.cstproxy.com/edocacquisition/2022.

Key Points: 
  • An extraordinary general meeting of the Companys shareholders (Special Meeting) to approve the Extension Amendment will be held on August 12, 2022 at 10:00 AM, Eastern Time and can be accessed virtually by visiting https://www.cstproxy.com/edocacquisition/2022.
  • The Companys shareholders of record at the close of business on the record date, July 18, 2022, are entitled to vote the ordinary shares of Edoc owned by them at the Special Meeting.
  • Every shareholders vote is important, regardless of the number of shares held, and the Company requests the prompt submission of votes.
  • The Company has made arrangements for shareholders to vote online, by telephone, or by mail, simply by following the instructions on their provided proxy card.

Calidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma

Retrieved on: 
Tuesday, August 2, 2022
Stem Cells, Biotechnology, FDA, Health, General Health, Oncology, Research, Infectious Diseases, Genetics, Science, Clinical Trials, Sale, PIPE, Food and Drug Administration, NSC, Person, Patient safety, Northwest Biotherapeutics, Adult, Safety, Clinical trial, Neuro, Security (finance), Securities Act of 1933, National Cancer Institute, National Comprehensive Cancer Network, Population, Neurosurgery, Research, U.S. Securities and Exchange Commission, Potyvirus, Prospectus, Cancer, Temozolomide, Technology, Proxy, Oncology, III, Business, Food, SEC, Failure, Board, Degenerative disease, COVID-19, Nature, FDA, Glioma, Brain tumor, Survival, Form, Name, Business architecture, Plan, Radiation, Neoplasm, Private Securities Litigation Reform Act, Risk, GMP, City of Hope, Trial of the century, Patient, Department, Suite, B cell, Regenerative medicine, Pharmaceutical industry, Vaccine, City, Edoc, Hope

The phase 1 physician-sponsored clinical trial will be an open-label, non-randomized, multicenter study.

Key Points: 
  • The phase 1 physician-sponsored clinical trial will be an open-label, non-randomized, multicenter study.
  • Secondary endpoints will evaluate treatment efficacy, including progression-free and overall survival as well as any immune response to NeuroNova.
  • Worldwide, an estimated 270,000 people were diagnosed with a primary brain tumor in 2020, with a five-year survival rate of only 5%.
  • Recurrent glioma patients have poor prognosis with a median survival of less than one year.

SETWorks Acquires EDoc, Modernizing Data Management For Iowa Disability Service Providers

Retrieved on: 
Tuesday, July 12, 2022
Data management, Record, Acquisition, Solution, DHS, Information, Disability, IACP, Organization, Iowa Department of Human Services, Human services, Possibilities, Documentation, COO, Edoc, Time, IME, Investment, Community, Industry, Software, Risk management, Management

KANSAS CITY, Mo., July 12, 2022 /PRNewswire/ -- SETWorks, an established provider of software for the disability service industry, today announced its acquisition of EDoc, the leading electronic documentation platform for Iowa intellectual and developmental disability (I/DD) service agencies. SETWorks purchased EDoc from Imagine the Possibilities, an Iowa I/DD service provider.

Key Points: 
  • The deal expands SETWorks disability service management software across the state, improving service delivery, outcomes.
  • The deal brings SETWorks' modern, disability service management platform and industry expertise to Iowa providers of all sizes.
  • SETWorks has longstanding relationships with the Iowa Department of Human Services (DHS), Iowa Medicaid Enterprise (IME), and Iowa Association of Community Providers (IACP).
  • Through these relationships SETWorks will continue to adapt the SETWorks platform to serve and empower Iowa providers.

Calidi Biotherapeutics Announces Appointment of W.K. Alfred Yung, M.D., to its Medical Advisory Board

Retrieved on: 
Tuesday, June 28, 2022
Science, Biotechnology, Research, Oncology, General Health, Health, FDA, Clinical Trials, FDA, Neuro, Patient, Business, Securities Act of 1933, B cell, Precision medicine, MD Anderson Cancer Center, Register, Potyvirus, COVID-19, Failure, Sale, U.S. Securities and Exchange Commission, Prospectus, Suite, Glioblastoma, Form, PIPE, Risk, Cancer, Person, Proxy, Business architecture, Neuro-Oncology (journal), Patient safety, Name, Plan, SEC, Brain, Private Securities Litigation Reform Act, Safety, Neuro-oncology, Nature, Northwest Biotherapeutics, Security (finance), Pharmaceutical industry, Vaccine, Risk management, Edoc

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company that is pioneering the development of stem cell-based delivery of oncolytic viruses, today announced the appointment of W.K.

Key Points: 
  • Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company that is pioneering the development of stem cell-based delivery of oncolytic viruses, today announced the appointment of W.K.
  • Alfred Yung, M.D., Professor, Neuro-Oncology at the MD Anderson Cancer Center, to its Medical Advisory Board.
  • Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery of oncolytic viruses for targeted therapy against difficult-to-treat cancers.
  • Calidi Biotherapeutics is advancing through the FDA approval process a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications.

Calidi Biotherapeutics to Present at Jefferies Healthcare Conference

Retrieved on: 
Thursday, June 2, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Name, PIPE, Protalix BioTherapeutics, Conference, Business architecture, Securities Act of 1933, Form, Business, Register, Nature, Proxy, Security (finance), Cancer, Failure, U.S. Securities and Exchange Commission, Sale, FDA, Plan, Private Securities Litigation Reform Act, Risk, Prospectus, COVID-19, SEC, Potyvirus, Patient safety, Person, Suite, Edoc

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering the development of stem cell-based delivery of oncolytic viruses, today announced that Stephen Thesing, Chief Business Officer, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:00 p.m.

Key Points: 
  • Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering the development of stem cell-based delivery of oncolytic viruses, today announced that Stephen Thesing, Chief Business Officer, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:00 p.m.
  • Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery of oncolytic viruses for targeted therapy against difficult-to-treat cancers.
  • Calidi Biotherapeutics is advancing through the FDA approval process a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications.
  • Edoc Acquisition Corp., Calidi Biotherapeutics, Inc., and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies or consents from Edoc Acquisition Corp. and Calidi Biotherapeutics, Inc. shareholders in connection with the proposed transaction.